ArticleBMC microbiology2026
Genomic characterization of extended-spectrum β-Lactamases (ESBLs)-producing Escherichia coli recovered from bloodstream infections in China.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBloodstream infections (BSIs) caused by Escherichia coli represent a major clinical challenge, particularly among elderly patients and those with urinary catheters. The rising prevalence of extended-spectrum β-lactamase (ESBL)-producing strains further complicates therapeutic management and infection control. This study aimed to characterize the clinical features, antimicrobial resistance profiles, and genomic features of ESBL-producing E. coli isolates associated with BSIs in a county-level hospital in Zhejiang Province, China.
methodsA total of 236 non-duplicate E. coli isolates recovered from BSIs were collected between January 2021 and December 2023. Antimicrobial susceptibility testing (AST) was performed for all isolates. Of these, 144 isolates were successfully preserved for subsequent molecular analysis, among which 65 ESBL-producing isolates underwent whole-genome sequencing (WGS) for the detection of ESBL genes, phylogenetic grouping, multilocus sequence typing, serotyping, fimH typing, and core genome SNP analysis.
resultsMost patients were elderly women, and urinary tract infection was identified as the primary source of bacteremia. Resistance rates were low to piperacillin-tazobactam (2.14%) and cefoperazone-sulbactam (1.28%) but high to levofloxacin (35.74%), ceftriaxone (47.01%), cefuroxime (50.21%), and trimethoprim-sulfamethoxazole (56.17%); all isolates remained fully susceptible to imipenem, ertapenem, amikacin, and tigecycline. Among 144 isolates, 65 (45.1%) were ESBL producers, predominantly carrying blaCTX−M−27, followed by blaCTX−M−14, blaCTX−M−55, and blaCTX−M−15. Phylogenetic analysis showed that the majority of ESBL-producing isolates were assigned to phylogroups B2 and D, with ST131 as the dominant sequence type, strongly associated with O25:H4 and fimH30. Core genome SNP analysis revealed substantial genetic diversity, with closely related isolates mainly observed within the same patient over time.
conclusionsThis study highlights a substantial burden of ESBL-producing E. coli BSIs, dominated by the ST131-fimH30-O25:H4 clone carrying blaCTX−M−27, underscoring the need for enhanced surveillance, targeted antimicrobial therapy, and effective infection control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.